Navigation Links
ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin,Conjugate Data Presented at American Diabetes Association Annual,Meeting

MONTREAL, June 19 /CNW/ - ConjuChem Biotechnologies (TSX:CJB) today announced that data relating to its proprietary PC-DAC(TM):Exendin-4 Albumin Conjugate for the treatment of Type 2 diabetes will be presented at the 67th Scientific Sessions of the American Diabetes Association (ADA) to be held June 22-26, 2007 in Chicago, IL. The ADA's annual Scientific Sessions meeting is one of the largest gatherings of health care professionals involved in diabetes research and the delivery of diabetes care.

"These encouraging results from our Phase I/II multiple-dose clinical studies demonstrate that our PC-DAC(TM):Exendin-4 Albumin Conjugate is a well-tolerated and effective therapy," said Mark D. Perrin, President and CEO. "The data was further evidence of our compound's potential to become a once-weekly treatment for Type 2 diabetes."

The study titled "PC-DAC(TM):Exendin-4 (CJC-1134-PC) Demonstrates Safety and Efficacy as an Adjunct Therapy to Metformin: A Randomized, Double-Blind, Placebo-Controlled, One Month Phase I/II Study in 70 Patients with Type 2 Diabetes Mellitus", authored by Maggie Wang et al., was featured as a late breaking abstract. Seventy patients were enrolled in US and Canada and randomized to 1 mg, 2mg, 3mg of PC-DAC(TM):Exendin-4 or placebo treatment groups. All three treatment groups experienced reductions in fasting plasma glucose that were statistically significant versus baseline (p less than 0.005) and versus placebo (p less than 0.03) over the 5-week treatment period. Median HbA1c values decreased from baseline by 0.7%, 0.8% and 0.9% in the 1mg, 2mg, and 3mg groups, respectively, at the end of the study (Day 63) and were statistically significant (p less than 0.03 by ANCOVA) between pooled active patients (n=52) and placebo (n=18). There was no significant change in weight in the treatment cohorts (baseline 81-85kg) at the end of the treatment period. Generally low-titer antibodies were de
'"/>




Page: 1 2 3

Related medicine technology :

1. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
2. Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:10/31/2014)... 2014  Encision Inc. (OTCQB:ECIA), a medical device company ... burns in minimally invasive surgery, today announced financial results ... 2014. The Company posted quarterly net revenue ... $414 thousand, or $(0.04) per share. These results compare ... loss of $50 thousand, or $(0.01) per share, in ...
(Date:10/31/2014)... , Oct. 31, 2014 /CNW Telbec/ - Ergoresearch ... its strategic plan, for accelerated growth in terms of ... and revenues reached $17,862,341. Net income amounted to $1,230,153. ... for the first time in the Company,s history. ... Company joined the forces of its subsidiaries, merging in ...
(Date:10/31/2014)... Research and ... the  "Process Validation in the US and EU ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,Key topics to include:  ... to Process Validation for Pharmaceutical and Biopharmaceutical Products ... Process Validation Guidance EU Process Validation ...
Breaking Medicine Technology:Encision Reports Second Quarter Fiscal Year 2015 Results 2Encision Reports Second Quarter Fiscal Year 2015 Results 3Encision Reports Second Quarter Fiscal Year 2015 Results 4Encision Reports Second Quarter Fiscal Year 2015 Results 5Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 2Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 3Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 4Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 5Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4
... mass index (BMI) should be taken into account when assessing ... Cancer Treatment Centers of America (CTCA), ... of vitamin D compared to non-obese patients. , , ... , The association between vitamin D and obesity remains unsettled ...
... Calif., June 12 Masimo (Nasdaq: MASI ... and Low-Perfusion pulse oximetry, announced today that three new ... Masimo PVI as a noninvasive and continuous measure of ... at the European Society of Anaesthesiology (ESA) Annual Congress ...
Cached Medicine Technology:Researchers Say More Aggressive Vitamin D Supplementation Needed in Obese Cancer Patients 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6
(Date:10/31/2014)... 31, 2014 (HealthDay News) -- Sleep apnea may make it ... you parked your car or left your house keys, a ... sleep apnea showed that this ability -- called spatial memory ... (REM) sleep, even when other stages of sleep weren,t affected. ... dreams typically occur. "We,ve shown for the first time ...
(Date:10/31/2014)... lab device to give cancer researchers an unprecedented microscopic ... spread through the body, causing more than 90 percent ... tumor cells travel, the device could uncover new ways ... the university,s Whiting School of Engineering and its Institute ... new system recently in the journal Cancer Research ...
(Date:10/31/2014)... combination that can trigger the self-destruct process in lung ... according to research that will be presented at the ... next week*. , When healthy cells are no longer ... self destruction. But cancer cells swerve away from this ... grow out of control – causing tumours to form. ...
(Date:10/31/2014)... Phoenix, AZ (PRWEB) October 31, 2014 ... off all dental treatments for November. Whether patients simply need ... there is no better time than now to get that ... but many patients put off routine and even essential treatments ... patients can enjoy substantial savings on any treatments offered by ...
(Date:10/31/2014)... 31, 2014 Adults 65 and ... their Medicare coverage during the current open enrollment ... library for step-by-step guidance, the company announced today. ... on choosing the correct Medicare Advantage plan, understanding ... open enrollment. , “With just one month remaining ...
Breaking Medicine News(10 mins):Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3Health News:Scientists trigger self-destruct switch in lung cancer cells 2Health News:Phoenix Dentist, Dr. Christy, is Now Offering Ten Percent Off On All Dental Treatments for the Month of November 2
... Indian state of Tamil Nadu has decided to transfer the ... for the anti-cancer drug Glivec to the Intellectual Property Appellate ... setback to the pharma multinational. ,For it cannot ... Appellate Board’s ruling too can be challenged it in the ...
... United States, are now spreading their wings with distant shores ... Hopkins clinic will be set up at Tokyo, Japan. ... Japan’s growing discontent with the national health-care system. Accordingly, around ... by caring for an aging population. This has even got ...
... the ultimate cocktail dress: it's made from red wine, smells like ... spilled on it.// ,The fabric is actually the papery ... finds its way in. ,To form the dress, the wet, ... partially dry out. Deflate the doll, and the finished dress comes ...
... towards a successful womb transplant. // ,Four sheep ... reconnected, Swedish scientists say. ,Professor Mats Brannstrom ... - where the same womb is removed and reconnected. ... in the study developed fatal complications and hence it would ...
... circuitry using textile's threads to monitor the medical condition ... ,This may sound complex, but it is a ... ,In 1996, researchers at Georgia Institute of Technology ... with sensors capable of monitoring a patient's heartbeat, temperature ...
... Center for Devices and Radiological Health of the Food and ... Danek to market INFUSE? Bone Graft for use in dental ... FDA as a replacement for autograft in spinal fusion procedures ... ,"FDA approval of INFUSE marks a major step forward ...
Cached Medicine News:Health News:Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board 2Health News:Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board 3Health News:John Hopkins Hospitals- Now at Tokyo 2Health News:Womb Transplant Pregnancy Success 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: